

Myelodysplastic Syndrome (MDS) Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Treatment Type (Stem Cell Transplant, Immune Treatments, Chemotherapy, Immunomodulatory Drugs(Lenalidomide, others), Anti-anemics(Luspatercept-aamt, others), Others(Cytarabine, Daunorubicin, Idarubicin, INQOVI)), By End user (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, and Competition

<https://marketpublishers.com/r/MDA0F0FB29E2EN.html>

Date: November 2023

Pages: 182

Price: US\$ 4,900.00 (Single User License)

ID: MDA0F0FB29E2EN

Abstracts

Global Myelodysplastic Syndrome (MDS) Treatment Market has valued at USD 2.84 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.22% through 2028. Myelodysplastic Syndrome (MDS) is a group of blood disorders characterized by dysfunctional blood cell production in the bone marrow. It affects the production of red blood cells, white blood cells, and platelets, leading to a variety of symptoms and complications. Over the years, significant progress has been made in the diagnosis and treatment of MDS, leading to a growing global market for MDS treatment. MDS primarily affects older adults, but it can occur at any age. It is often considered a pre-leukemic condition because it can progress to acute myeloid leukemia (AML). The exact cause of MDS is still unknown, but it is believed to be linked to genetic mutations, exposure to certain chemicals, and radiation therapy.

The global MDS treatment market is witnessing steady growth, driven by several

factors. As the global population continues to age, the incidence of MDS is expected to rise. This demographic shift contributes to an increased demand for MDS treatments. Growing awareness among healthcare providers and patients about MDS has led to earlier diagnosis and intervention, further boosting the market's growth. Developing economies are becoming more significant players in the MDS treatment market due to improvements in healthcare infrastructure and access to advanced therapies. Continued investments in MDS research and development by pharmaceutical companies and government agencies are expected to yield innovative treatment options and expand the market.

The global Myelodysplastic Syndrome treatment market has witnessed remarkable advancements in recent years, offering new hope to patients diagnosed with this challenging condition. Targeted therapies, personalized medicine, improved supportive care, and ongoing clinical trials are transforming the landscape of MDS treatment. With a growing aging population and increasing awareness, the market for MDS treatments is poised for continued expansion, ultimately leading to better outcomes and improved quality of life for patients battling this disease.

Key Market Drivers

Rising Prevalence of Respiratory Diseases is Driving the Global Myelodysplastic Syndrome (MDS) Treatment Market

Respiratory diseases have become a significant global health concern, affecting millions of individuals worldwide. These ailments, which include conditions like asthma, chronic obstructive pulmonary disease (COPD), and bronchitis, can severely impact a person's quality of life and, in some cases, be life-threatening. The rising prevalence of respiratory diseases has led to increased demand for effective treatment options, and one such solution that has gained prominence in recent years is Myelodysplastic Syndrome (MDS) Treatment. Myelodysplastic Syndrome (MDS) Treatment are a form of medication delivery that involves inhaling a nebulized solution through a specialized device. This method is particularly effective for delivering medication directly to the respiratory system, making it a vital component in managing and treating respiratory diseases. The global Myelodysplastic Syndrome (MDS) Treatment market has witnessed significant growth in response to the increasing burden of respiratory diseases.

One of the most apparent drivers of the global Myelodysplastic Syndrome (MDS) Treatment market is the growing prevalence of respiratory diseases. Factors such as air

pollution, smoking, and an aging population have contributed to the increasing incidence of conditions like asthma, COPD, and respiratory infections. As these diseases become more prevalent, the demand for effective treatment options, including Myelodysplastic Syndrome (MDS) Treatment, continues to rise. Modern respule devices are designed with the patient in mind. They are often portable, easy to use, and require minimal maintenance. This user-friendly approach has made Myelodysplastic Syndrome (MDS) Treatment a preferred choice for many patients, including children and the elderly, who may find traditional inhalers challenging to operate. Increased efforts in raising awareness about respiratory diseases and the benefits of Myelodysplastic Syndrome (MDS) Treatment have contributed to market growth. Healthcare providers and organizations are actively educating both patients and caregivers about the advantages of using Myelodysplastic Syndrome (MDS) Treatment in managing respiratory conditions, leading to higher adoption rates. The expansion and improvement of healthcare infrastructure, especially in developing countries, have made Myelodysplastic Syndrome (MDS) Treatment more accessible to a broader population. This improved accessibility has resulted in greater demand for these devices and the medications they deliver.

Growing Aging Population is Driving the Global Myelodysplastic Syndrome (MDS) Treatment Market

The world is experiencing a demographic shift of monumental proportions – the aging of the global population. As people live longer lives, the prevalence of chronic respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis, has risen significantly. This demographic trend has given rise to a burgeoning market for respiratory treatments, with Myelodysplastic Syndrome (MDS) Treatment emerging as a promising delivery method for these medications.

The aging population phenomenon is characterized by an increase in the number of elderly individuals worldwide. This is primarily due to advances in healthcare, improved living conditions, and declining birth rates. The United Nations estimates that by 2050, the global population aged 60 and over will reach 2.1 billion, nearly double the number in 2017. As people age, their risk of developing respiratory ailments like COPD, asthma, and pneumonia increases significantly. Chronic respiratory diseases are often debilitating, reducing the quality of life and increasing healthcare costs. Consequently, there is a growing demand for innovative and effective respiratory treatments to manage these conditions, and Myelodysplastic Syndrome (MDS) Treatment have emerged as a key player in this arena.

The aging population's increased susceptibility to respiratory diseases has spurred the demand for Myelodysplastic Syndrome (MDS) Treatment. Myelodysplastic Syndrome (MDS) Treatment are preferred by elderly patients due to their ease of use and effectiveness. They require minimal effort to inhale the medication, making them more accessible for individuals with limited lung capacity or mobility issues. Myelodysplastic Syndrome (MDS) Treatment allow for a lower dosage of medication while achieving the same therapeutic effect, reducing the risk of side effects, which is crucial for older individuals who may be more sensitive to drugs. Chronic respiratory diseases require ongoing management, and Myelodysplastic Syndrome (MDS) Treatment make it easier for elderly patients to adhere to their treatment plans, thus improving their overall quality of life. The rising demand for Myelodysplastic Syndrome (MDS) Treatment has led to increased research and development in this field, resulting in a wider variety of medications being available in this format.

Key Market Challenges

Regulatory Hurdles

One of the primary challenges facing the Myelodysplastic Syndrome (MDS) Treatment market is navigating complex regulatory requirements. Different countries have varying regulatory frameworks for the approval and marketing of respiratory drugs and delivery devices. The need for rigorous clinical trials and adherence to strict quality standards can significantly delay product launches and increase development costs. Companies operating in this space must have a deep understanding of the regulatory landscape and invest in compliance to ensure market access.

Competitive Landscape

The Myelodysplastic Syndrome (MDS) Treatment market is highly competitive, with several well-established pharmaceutical companies and emerging players vying for market share. Developing innovative products that provide superior therapeutic outcomes while remaining cost-effective is essential for success. Market incumbents must continuously invest in research and development to stay ahead, while new entrants face the challenge of breaking into an already crowded field.

Technological Advancements

The rapid pace of technological advancements in the Myelodysplastic Syndrome (MDS) Treatment market poses both opportunities and challenges. On one hand,

advancements in nebulizer technology have led to more efficient and patient-friendly devices. On the other hand, companies must continuously invest in research and development to keep up with the latest innovations. Additionally, the adoption of digital health solutions and the integration of smart inhalers into treatment plans introduce new complexities, such as data security and patient engagement.

Pricing Pressures

Price pressures and cost containment measures in healthcare systems around the world are impacting the Myelodysplastic Syndrome (MDS) Treatment market. Payers, including governments and insurance companies, are increasingly focused on cost-effectiveness and value-based healthcare. This puts pressure on pharmaceutical companies to demonstrate the cost-effectiveness of their products, negotiate favorable reimbursement terms, and find ways to reduce the overall cost of treatment for patients.

Supply Chain Disruptions

The COVID-19 pandemic exposed vulnerabilities in global supply chains, affecting the production and distribution of pharmaceutical products, including Myelodysplastic Syndrome (MDS) Treatment. Delays in the procurement of raw materials, transportation disruptions, and supply chain bottlenecks can impact product availability and lead to increased costs. Companies must enhance their supply chain resilience to mitigate these risks.

Patient Education and Adherence

Ensuring that patients properly understand how to use Myelodysplastic Syndrome (MDS) Treatment and adhere to their treatment regimens is crucial for effective disease management. Poor patient education and non-adherence can lead to suboptimal treatment outcomes and increased healthcare costs. The Myelodysplastic Syndrome (MDS) Treatment market faces the challenge of developing effective educational materials and technologies to support patient adherence and self-management.

Market Access and Reimbursement

Access to the Myelodysplastic Syndrome (MDS) Treatment market can be hindered by challenges related to reimbursement. Navigating the reimbursement landscape in different countries, securing favorable reimbursement rates, and addressing payer requirements for real-world evidence can be complex and time-consuming. Companies

must invest in health economic studies and value demonstration to improve market access.

Key Market Trends

Technological Advancements

Technological advancements have consistently played a pivotal role in transforming the landscape of healthcare. One such domain where this transformation is prominently visible is in the treatment of Myelodysplastic Syndrome (MDS), a group of bone marrow disorders that hinder the production of healthy blood cells. The Global Myelodysplastic Syndrome (MDS) Treatment Market is experiencing a significant boost, thanks to the remarkable strides made in technology and research.

One of the most significant breakthroughs in MDS treatment has been the ability to conduct comprehensive genetic profiling of patients. Advanced genomic sequencing technologies enable doctors to identify specific genetic mutations that drive the development of MDS. This information is crucial in tailoring personalized treatment plans and predicting disease progression accurately. With a better understanding of the genetic basis of MDS, pharmaceutical companies are developing targeted therapies that specifically address the underlying genetic abnormalities. These therapies are more effective and have fewer side effects compared to traditional chemotherapy.

Hematopoietic Stem Cell Transplantation (HSCT) is a critical treatment option for MDS, but it comes with significant risks. Technological advancements in stem cell collection and transplantation techniques have improved the safety and success rates of HSCT, making it a viable option for more patients. Technology has also improved the quality of supportive care for MDS patients. Advanced imaging techniques help in monitoring disease progression, while telemedicine allows patients to consult with specialists from the comfort of their homes, especially during the COVID-19 pandemic. Innovative drug delivery systems, such as nanotechnology-based drug carriers, ensure precise and targeted drug delivery, minimizing damage to healthy cells and enhancing the therapeutic effects of medications.

Treatment Type Insights

The Stem Cell Transplant segment is projected to experience rapid growth during the forecast period. Stem cell transplant is currently the only potentially curative treatment for Myelodysplastic Syndrome. It offers the chance for a long-term remission or even a

complete cure for some patients. This curative potential makes it a vital option for Myelodysplastic Syndrome patients, especially those with high-risk disease or those who have progressed to acute myeloid leukemia (AML). Myelodysplastic Syndrome is characterized by the presence of abnormal blood-forming stem cells in the bone marrow, leading to inadequate production of healthy blood cells. Stem cell transplant involves replacing the patient's diseased or malfunctioning hematopoietic stem cells with healthy ones from a donor. This effectively removes the source of the MDS and allows for the production of normal blood cells. Over the years, advancements in stem cell transplant techniques have expanded the pool of potential donors. In addition to traditional bone marrow transplants, peripheral blood stem cell and cord blood transplants are now viable options. This has made it easier for Myelodysplastic Syndrome patients to find suitable donors, increasing the overall success rate of transplants. Traditional stem cell transplants require high-intensity chemotherapy and radiation to prepare the patient's body for the transplant. However, reduced-intensity conditioning (RIC) regimens have been developed and are increasingly used. RIC is less toxic and allows older or less fit patients to undergo transplantation, broadening its applicability.

End User Insights

The Hospitals & Clinics segment is projected to experience rapid growth during the forecast period. Treating Myelodysplastic Syndrome often requires a multidisciplinary approach involving hematologists, oncologists, pathologists, and other medical professionals. Hospitals and clinics are well-suited to facilitate collaboration among these specialists, ensuring that patients receive the best possible care. Accurate diagnosis of Myelodysplastic Syndrome is essential for determining the appropriate treatment plan. Hospitals and clinics have access to advanced diagnostic tools, such as bone marrow biopsies, cytogenetic testing, and molecular profiling, which are essential for identifying and classifying Myelodysplastic Syndrome. Myelodysplastic Syndrome treatment options vary depending on the subtype and severity of the disease. Hospitals and clinics are well-equipped to provide a range of treatment modalities, including chemotherapy, bone marrow transplantation, supportive care, and experimental therapies as part of clinical trials.

Regional Insights

North America emerged as the dominant player in the global Myelodysplastic Syndrome (MDS) Treatment market in 2022, holding the largest market share in terms of value. North America, particularly the United States and Canada, boasts advanced healthcare

infrastructure, world-class medical facilities, and a strong pharmaceutical industry. This infrastructure can support cutting-edge research, clinical trials, and the development of innovative treatments for diseases like MDS. North America is home to many leading medical research institutions, universities, and pharmaceutical companies. These organizations often collaborate on MDS research, leading to breakthroughs in understanding the disease and developing novel treatment approaches. North America has a robust biotechnology and pharmaceutical industry with substantial investments in drug discovery and development. This financial support can accelerate the development of new therapies for MDS.

Key Market Players

AbbVie Inc.

Accord Healthcare Limited

Bristol-Myers Squibb Company

Jazz Pharmaceuticals Inc.

Novartis AG

Lupin Pharmaceuticals Inc.

Otsuka America Pharmaceutical Inc.

Onconova Therapeutics Inc.

Takeda Pharmaceutical Company Limited

Astex Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Myelodysplastic Syndrome (MDS) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Myelodysplastic Syndrome (MDS) Treatment Market, By Treatment Type:

Stem Cell Transplant

Immune Treatments

Chemotherapy

Immunomodulatory Drugs

Anti-anaemics

Others

Myelodysplastic Syndrome (MDS) Treatment Market, By End User:

Hospitals & Clinics

Ambulatory Care Centers

Others

Myelodysplastic Syndrome (MDS) Treatment Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Myelodysplastic Syndrome (MDS) Treatment Market.

Available Customizations:

Myelodysplastic Syndrome (MDS) Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecas...

Global Myelodysplastic Syndrome (MDS) Treatment market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validations
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) TREATMENT MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Treatment Type (Stem Cell Transplant, Immune Treatments, Chemotherapy, Immunomodulatory Drugs(Lenalidomide, others), Anti-anemics(Luspatercept-aamt, others), Others(Cytarabine, Daunorubicin, Idarubicin, INQOVI))

5.2.2. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)

5.2.3. By Region

5.2.4. By Company (Shares of Top 5 Market Players)

5.3. Market Map

5.3.1. By Treatment Type

5.3.2. By End user

5.3.3. By Region

6. NORTH AMERICA MYELOYDYSPLASTIC SYNDROME (MDS) TREATMENT MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Treatment Type

6.2.2. By End user

6.2.3. By Country

6.2.3.1. United States Myelodysplastic Syndrome (MDS) Treatment Market Outlook

6.2.3.1.1. Market Size & Forecast

6.2.3.1.1.1. By Value

6.2.3.1.2. Market Share & Forecast

6.2.3.1.2.1. By Treatment Type

6.2.3.1.2.2. By End user

6.2.3.2. Canada Myelodysplastic Syndrome (MDS) Treatment Market Outlook

6.2.3.2.1. Market Size & Forecast

6.2.3.2.1.1. By Value

6.2.3.2.2. Market Share & Forecast

6.2.3.2.2.1. By Treatment Type

6.2.3.2.2.2. By End user

6.2.3.3. Mexico Myelodysplastic Syndrome (MDS) Treatment Market Outlook

6.2.3.3.1. Market Size & Forecast

6.2.3.3.1.1. By Value

6.2.3.3.2. Market Share & Forecast

6.2.3.3.2.1. By Treatment Type

6.2.3.3.2.2. By End user

7. EUROPE MYELOYDYSPLASTIC SYNDROME (MDS) TREATMENT MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Treatment Type

7.2.2. By End user

7.2.3. By Country

7.2.3.1. France Myelodysplastic Syndrome (MDS) Treatment Market Outlook

7.2.3.1.1. Market Size & Forecast

7.2.3.1.1.1. By Value

7.2.3.1.2. Market Share & Forecast

7.2.3.1.2.1. By Treatment Type

7.2.3.1.2.2. By End user

7.2.3.2. Germany Myelodysplastic Syndrome (MDS) Treatment Market Outlook

7.2.3.2.1. Market Size & Forecast

7.2.3.2.1.1. By Value

7.2.3.2.2. Market Share & Forecast

7.2.3.2.2.1. By Treatment Type

7.2.3.2.2.2. By End user

7.2.3.3. United Kingdom Myelodysplastic Syndrome (MDS) Treatment Market Outlook

7.2.3.3.1. Market Size & Forecast

7.2.3.3.1.1. By Value

7.2.3.3.2. Market Share & Forecast

7.2.3.3.2.1. By Treatment Type

7.2.3.3.2.2. By End user

7.2.3.4. Italy Myelodysplastic Syndrome (MDS) Treatment Market Outlook

7.2.3.4.1. Market Size & Forecast

7.2.3.4.1.1. By Value

7.2.3.4.2. Market Share & Forecast

7.2.3.4.2.1. By Treatment Type

7.2.3.4.2.2. By End user

7.2.3.5. Spain Myelodysplastic Syndrome (MDS) Treatment Market Outlook

7.2.3.5.1. Market Size & Forecast

7.2.3.5.1.1. By Value

7.2.3.5.2. Market Share & Forecast

7.2.3.5.2.1. By Treatment Type

7.2.3.5.2.2. By End user

8. ASIA PACIFIC MYELOYDYSPLASTIC SYNDROME (MDS) TREATMENT MARKET

OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Treatment Type

8.2.2. By End user

8.2.3. By Country

8.2.3.1. China Myelodysplastic Syndrome (MDS) Treatment Market Outlook

8.2.3.1.1. Market Size & Forecast

8.2.3.1.1.1. By Value

8.2.3.1.2. Market Share & Forecast

8.2.3.1.2.1. By Treatment Type

8.2.3.1.2.2. By End user

8.2.3.2. India Myelodysplastic Syndrome (MDS) Treatment Market Outlook

8.2.3.2.1. Market Size & Forecast

8.2.3.2.1.1. By Value

8.2.3.2.2. Market Share & Forecast

8.2.3.2.2.1. By Treatment Type

8.2.3.2.2.2. By End user

8.2.3.3. South Korea Myelodysplastic Syndrome (MDS) Treatment Market Outlook

8.2.3.3.1. Market Size & Forecast

8.2.3.3.1.1. By Value

8.2.3.3.2. Market Share & Forecast

8.2.3.3.2.1. By Treatment Type

8.2.3.3.2.2. By End user

8.2.3.4. Japan Myelodysplastic Syndrome (MDS) Treatment Market Outlook

8.2.3.4.1. Market Size & Forecast

8.2.3.4.1.1. By Value

8.2.3.4.2. Market Share & Forecast

8.2.3.4.2.1. By Treatment Type

8.2.3.4.2.2. By End user

8.2.3.5. Australia Myelodysplastic Syndrome (MDS) Treatment Market Outlook

8.2.3.5.1. Market Size & Forecast

8.2.3.5.1.1. By Value

8.2.3.5.2. Market Share & Forecast

8.2.3.5.2.1. By Treatment Type

8.2.3.5.2.2. By End user

9. SOUTH AMERICA MYELOYDYSPLASTIC SYNDROME (MDS) TREATMENT MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Treatment Type

9.2.2. By End user

9.2.3. By Country

9.2.3.1. Brazil Myelodysplastic Syndrome (MDS) Treatment Market Outlook

9.2.3.1.1. Market Size & Forecast

9.2.3.1.1.1. By Value

9.2.3.1.2. Market Share & Forecast

9.2.3.1.2.1. By Treatment Type

9.2.3.1.2.2. By End user

9.2.3.2. Argentina Myelodysplastic Syndrome (MDS) Treatment Market Outlook

9.2.3.2.1. Market Size & Forecast

9.2.3.2.1.1. By Value

9.2.3.2.2. Market Share & Forecast

9.2.3.2.2.1. By Treatment Type

9.2.3.2.2.2. By End user

9.2.3.3. Colombia Myelodysplastic Syndrome (MDS) Treatment Market Outlook

9.2.3.3.1. Market Size & Forecast

9.2.3.3.1.1. By Value

9.2.3.3.2. Market Share & Forecast

9.2.3.3.2.1. By Treatment Type

9.2.3.3.2.2. By End user

10. MIDDLE EAST & AFRICA MYELOYDYSPLASTIC SYNDROME (MDS) TREATMENT MARKET OUTLOOK

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Treatment Type

10.2.2. By End user

10.2.3. By Country

10.2.3.1. South Africa Myelodysplastic Syndrome (MDS) Treatment Market Outlook

10.2.3.1.1. Market Size & Forecast

- 10.2.3.1.1.1. By Value
- 10.2.3.1.2. Market Share & Forecast
 - 10.2.3.1.2.1. By Treatment Type
 - 10.2.3.1.2.2. By End user
- 10.2.3.2. Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
 - 10.2.3.2.1. Market Size & Forecast
 - 10.2.3.2.1.1. By Value
 - 10.2.3.2.2. Market Share & Forecast
 - 10.2.3.2.2.1. By Treatment Type
 - 10.2.3.2.2.2. By End user
- 10.2.3.3. UAE Myelodysplastic Syndrome (MDS) Treatment Market Outlook
 - 10.2.3.3.1. Market Size & Forecast
 - 10.2.3.3.1.1. By Value
 - 10.2.3.3.2. Market Share & Forecast
 - 10.2.3.3.2.1. By Treatment Type
 - 10.2.3.3.2.2. By End user

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Recent Development
- 12.2. Mergers & Acquisitions
- 12.3. Technology Launches

13. COMPETITIVE LANDSCAPE

- 13.1. AbbVie Inc.
 - 13.1.1. Business Overview
 - 13.1.2. End user Offerings
 - 13.1.3. Recent Developments
 - 13.1.4. Key Personnel
 - 13.1.5. SWOT Analysis
- 13.2. Accord Healthcare Limited
- 13.3. Bristol-Myers Squibb Company
- 13.4. Jazz Pharmaceuticals Inc.

- 13.5. Novartis AG
- 13.6. Lupin Pharmaceuticals Inc.
- 13.7. Otsuka America Pharmaceutical Inc.
- 13.8. Onconova Therapeutics Inc.
- 13.9. Takeda Pharmaceutical Company Limited
- 13.10. Astex Pharmaceuticals, Inc.

14. STRATEGIC RECOMMENDATIONS

About us & Disclaimer

I would like to order

Product name: Myelodysplastic Syndrome (MDS) Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Treatment Type (Stem Cell Transplant, Immune Treatments, Chemotherapy, Immunomodulatory Drugs(Lenalidomide, others), Anti-anemics(Luspatercept-aamt, others), Others(Cytarabine, Daunorubicin, Idarubicin, INQOVI)), By End user (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, and Competition

Product link: <https://marketpublishers.com/r/MDA0F0FB29E2EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MDA0F0FB29E2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970